Intravenous Delivery of Lung‐Targeted Nanofibers for Pulmonary Hypertension in Mice

Abstract

Pulmonary hypertension is a highly morbid disease with no cure. Available treatments are limited by systemic adverse effects due to non‐specific biodistribution. Self‐assembled peptide amphiphile (PA) nanofibers are biocompatible nanomaterials that can be modified to recognize specific biological markers to provide targeted drug delivery and reduce off‐target toxicity. Here, PA nanofibers that target the angiotensin I‐converting enzyme and the receptor for advanced glycation end‐products (RAGE) are developed, as both proteins are overexpressed in the lung with pulmonary hypertension. It is demonstrated that intravenous delivery of RAGE‐targeted nanofibers containing the targeting epitope LVFFAED (LVFF) significantly accumulated within the lung in a chronic hypoxia‐induced pulmonary hypertension mouse model. Using 3D light sheet fluorescence microscopy, it is shown that LVFF nanofiber localization is specific to the diseased pulmonary tissue with immunofluorescence analysis demonstrating colocalization of the targeted nanofiber to RAGE in the hypoxic lung. Furthermore, biodistribution studies show that significantly more LVFF nanofibers localized to the lung compared to major off‐target organs. Targeted nanofibers are retained within the pulmonary tissue for 24 h after injection. Collectively, these data demonstrate the potential of a RAGE‐targeted nanomaterial as a drug delivery platform to treat pulmonary hypertension.

ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy

“… 33 Therefore, various nanoplatforms have been developed to enhance the tumor-specific accumulation, cellular uptake and intracellular release of chemotherapeutics while decrease its efflux, nonspecific distribution and systemic toxicity. 34 The entrapment of DOX into PGla-PPBP nanoparticles could significantly improve cellular uptake in 4T1 cells, 2-fold than that of free DOX after 4 h incubation. Cellular uptake in MDA-MB-231 cells showed a similar tendency, in which DOX@NPs increased three times compared to free DOX after 4 h incubation.…”

Nanomaterials-based vaccines to target intracellular bacterial pathogens

“…or i.v. vaccination (Si et al, 2018;Marulanda et al, 2021). Histological examination of tissues from animals vaccinated with manganese iron oxide NPs revealed minimal inflammation in the lungs following i.n.…”

Nanotechnology Innovations in Pediatric Cardiology and Cardiovascular Medicine: A Comprehensive Review

“…Attempts have also been made to treat cardiomyopathies by inducing the formation of new mature cardiomyocytes [53], but the results were unsatisfactory. In some studies, attempts were made to inject several types of bone marrow-derived cells into dilated cardiomyopathy hearts, but severe side effects such as arrhythmia or tumors arose [74][75][76][77]. Other authors attempted to transform fibroblasts into contractile cardiomyocytes [75] by using cardiac-specific transcription factors or mitochondrial RNA to induce cardiomyocyte regeneration and proliferation [40].…”

“…Nanotechnology has emerged as a promising frontier for innovative and targeted interventions. In mice, Marulanda et al proposed an intravenous delivery system for lung-targeted nanofibers, aiming to decrease pulmonary hypertension [76]. Their results showed promising perspectives, especially for specific proteins overexpressed in this condition, such as the receptor for advanced glycation end-products (REGE) [76].…”